Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | CMA1 | P23946 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.35 |
| ▸ | F13A1 | P00488 | 1/20 | 0.33 |
| ▸ | TGM2 | P21980 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24691320 | 0.89 | CTSV (0.35) | CTSVCTSLCTSBELANECMA1 | |
| SCHEMBL24691121 | 0.89 | CTSV (0.36) | CTSVCTSLCTSBELANECMA1 | |
| SCHEMBL24960453 | 0.85 | CTSV (0.35) | CTSVCTSLCTSBELANECMA1 | |
| SCHEMBL27434262 | 0.84 | CCR1 (0.36) | CTSVCTSLCTSBELANECMA1 | |
| SCHEMBL26223479 | 0.83 | CTSV (0.34) | CTSVCTSLCTSBELANECMA1 | |
| SCHEMBL30251895 | 0.82 | AAK1 (0.36) | CTSVCTSLCTSBELANECMA1 | |
| SCHEMBL24691268 | 0.82 | AAK1 (0.36) | CTSVCTSLCTSBELANECMA1 | |
| SCHEMBL27434307 | 0.82 | CTSV (0.44) | CTSVCTSLCTSBELANECMA1 | |
| SCHEMBL24690585 | 0.80 | DPP4 (0.35) | CTSVCTSLCTSBELANECMA1 | |
| SCHEMBL16316336 | 0.80 | F13A1 (0.37) | CTSVCTSLCTSBELANECMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122153-A1 | Protease Inhibitors as Antivirals | ACEA Therapeutics, Inc. (US) | 2025-04-17 | — | — | US | disclosed |
| US-11987554-B2 | Protease inhibitors as antivirals | VIVASOR, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| EP-4347034-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACEA Therapeutics, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-117769541-A | protease inhibitors as antiviral agents | 艾森医药有限公司 | 2024-03-26 | — | — | CN | disclosed |
| US-20230322668-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACEA Therapeutics, Inc. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322668-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACEA Therapeutics, Inc. (US) | 2023-10-12 | — | — | US | disclosed |
| US-11753373-B2 | Protease inhibitors as antivirals | ACEA Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753373-B2 | Protease inhibitors as antivirals | ACEA Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230026438-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACEA Therapeutics, Inc. | 2023-01-26 | — | — | US | disclosed |
| WO-2022256434-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACEA Therapeutics, Inc. (US) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022256434-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACEA Therapeutics, Inc. (US) | 2022-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122153-A1 | Protease Inhibitors as Antivirals | ACE, ACE2, TMPRSS15 | CTSV 18/4885CTSL 4/4885CTSB 44/4885 |
| US-20230026438-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACE, ACE2, TMPRSS15 | CTSV 18/4885CTSL 4/4885CTSB 44/4885 |
| US-11753373-B2 | Protease inhibitors as antivirals | ACE, ACE2, TMPRSS15 | CTSV 18/4885CTSL 4/4885CTSB 44/4885 |
| US-11987554-B2 | Protease inhibitors as antivirals | ACE, ACE2, TMPRSS15 | CTSV 18/4885CTSL 4/4885CTSB 44/4885 |
| US-20230322668-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACE, ACE2, TMPRSS15 | CTSV 18/4885CTSL 4/4885CTSB 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.